Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

NCT03173417 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia

Interventions

BIOLOGICAL: IM19 CAR-T
DRUG: fludarabine and cyclophosphamide

Sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd.